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Abstract 
BACKGROUND: Mesenchymal stem cells (MSCs) may serve as immunoregulators by producing various anti-
inflammatory molecules. Under sufficient level of TNF-α, MSCs become activated and adopt immune-suppressive 
phenotype (MSCs type-2) by releasing various anti-inflammatory molecule including TGF-β and IL-10. However, 
the ability of MSC itself to produce IL-10 under TNF-α stimulation and the correlation of TGF-β production of 
MSCs to IL-10 level remains to be elucidated. 
AIM: In this study, MSCs were activated with various TNF-α doses to determine the increase of IL-10 and TGF-β 
level as well as its correlation. 
MATERIAL AND METHODS: This study used post-test only control group design, by using 3 study groups, 
consist of 1 control (C) and 2 treatments (T) (TNF-α = 5 and 10 ng/mL) with triplicate induced in MSC for 24 
hours, then the levels of IL-10 and TGF-β were measured by using ELISA assay. 
RESULTS: The results of this study showed a significant increase of TGF-β and IL-10 levels (p < 0.05) at TNF-α 
5 and 10 ng/mL dose of TNF-α. Moreover, there was a significant negative correlation between TGF-β and IL-10 
level on 5 and 10 ng/mL dose TNF-α treatment. 
CONCLUSION: Based on our study, we conclude that the 5 ng/mL dose of TNF-α is a sufficient dose for MSCs to 
suppress the inflammatory milieu. The higher increase of TGF beta is due to the controlled inflammation by IL-10. 
 
 
 
 
 
 
 
 
Introduction 
 
Mesenchymal stem cells (MSCs) are 
classically defined as multipotent cells expressing the 
surface markers of CD73, CD90, CD105, and lacking 
the expression of CD45, CD34, CD14 or CD11b, 
CD79a or CD19 and Human Leucocyte Antigen (HLA) 
class II. MSCs also can differentiate into osteocytes, 
chondrocytes and adipocytes under standard in-vitro 
differentiating conditions [1]. They can be isolated 
from the bone marrow, mobilised peripheral blood, 
cord blood, umbilical cord (UC), placenta, adipose 
tissue, dental pulp, and even the fetal liver and lungs. 
On the other side, the autologous use has several 
limitations in decreased growth and [2] differentiation 
capacity [3] [4] of cell numbers and age-related 
changes. UC-MSCs show a gene expression profile 
more pluripotent and stemness than BM-MSCs [5] [6]. 
MSCs display profound immunomodulatory properties 
by suppressing excessive inflammatory responses of 
a variety of immune disorders.  
Several studies have reported that MSCs 
actively interact and communicate with innate and 
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adaptive immune cells to ameliorate immune 
disorders [7] [8] [9]. Several clinical studies have 
shown that MSCs-based therapy effectively controls in 
various autoimmune disease, including Systemic 
Lupus Erythematosus (SLE), Graft versus Host 
Disease (GvHD), Rheumatoid Arthritis (RA), 
inflammatory bowel disease and multiple sclerosis.  
Furthermore, the ability of 
immunosuppressive of MSCs is regarding the 
production of cytokines such as TGF-β, IDO, NO, 
PGE2, IL-10 and TSG-6 [10] [11] [12]. IL-10 and TGF-
β1 serve as potent anti-inflammatory cytokines in 
controlling excessive inflammatory responses. 
Specifically IL-10 attenuates pro-inflammatory signals 
by inhibiting pro-inflammatory cytokines release 
particularly IFN-γ, IL-2, and TNF-α [13], while TGF-β1 
ameliorates immune disorder by generating of CD4 + 
CD25 + FoxP3 + Treg [14]. 
TNF-α is an active stimulator molecule in 
enhancing the secretion of various inflammatory 
cytokines. The previous study reported that TNF-α-
activated MSCs suppress inflammation by inducing IL-
10 production in macrophage cells but MSCs its self-
were not the source of IL-10 due to MSCs from IL-10
-/- 
mice were still effective in improving the survival of 
mice with sepsis [15]. A similar study has also 
described that IL-10 level decrease after 24 hours of 
intravenous infusion of mouse MSCs [16]. On the 
other side, TGF-β as immunosuppressive molecules 
constitutively produced by MSCs [17] also involved in 
promoting the T-cell production of IL-10 through direct 
activation of IL-10 promoter via Co-Smad4 [18]. Under 
sufficient level of TNF-α MSCs become activated and 
adopt immune-suppressive phenotype (MSCs type-2) 
by releasing various anti-inflammatory molecule 
including TGF-β and IL-10 [19]. However, the ability of 
MSC itself to produce IL-10 under TNF-α stimulation 
is yet unclear. Moreover, the correlation of TGF-β 
production of MSCs to IL-10 level remains to be 
elucidated.  
Therefore, in the present study, we explored 
the ability of MSCs in vitro in producing IL-10 and 
TGF-β at 5 and 10 ng/mL TNF-α for 24-hour 
incubation. 
 
 
Material and Methods 
 
Adult 19-day pregnant Wistar rats, weighing 
350-450 g, were provided by the animal husbandry 
department. The animal was used according to good 
animal practices, and animal experiments were 
approved by our local animal care.  
The umbilical cords were collected from the 
fetuses 19-day pregnant Wistar rats under general 
anaesthesia. The blood vessels were removed from 
umbilical cord, then the tissue parts under aseptic 
conditions were cut into smaller pieces and 
transferred to a T25 culture flask containing DMEM 
(Sigma-Aldrich, Louis St, MO) supporting with 10% 
Fetal Bovine Serum (FBS) (Gibco™ Invitrogen, NY, 
USA), 1% penicillin (100 U/mL)/streptomycin (100 
µg/mL) (Gibco™ Invitrogen, NY, USA). The UC 
tissues were incubated at 37°C in a humid 
atmosphere consisting of 5% CO2. The medium was 
renewed every 3 days, and after reaching 80% 
confluency (14 days), the cells were passaged. 
MSCs-like at passages 4–5 were used for the 
following experiments. 
MSCs-like surface antigens were analysed by 
flow cytometric analysis at the fourth passage. The 
cells were subsequently incubated in the dark with 
fluorescein isothiocyanate (FITC)-conjugated, 
Allophycocyanin (APC)-conjugated or phycoerythrin 
(PE)-conjugated monoclonal antibodies, including 
CD105, CD90 and CD73. FITC- APC- and PE-
conjugated isotypes were used as negative controls. 
The analysis was performed using BD Pharmingen
TM
 
(BD Bioscience, Franklin Lakes, NJ, USA) at 4°C for 
30 min. The cells were washed twice with 1% 
BSA/PBS, resuspended in 200 µL 1% BSA/ PBS and 
analysed by a flow cytometer (BD Biosciences, San 
Jose, CA, USA). 
To characterise the isolated cells, we further 
performed the osteogenic differentiation assay at the 
fourth passage. Osteogenesis was induced by 
osteogenic induction medium containing 10 mmol/L β 
glycerophosphate, 10
-7
 mol/L/ 0.1 μM 
dexamethasone, 50 μmol/L ascorbate-2-phosphate 
(Sigma-Aldrich, Louis St, MO) and supporting with 
10% FBS (Gibco™ Invitrogen, NY, USA) in DMEM 
(Sigma-Aldrich, Louis St, MO) at 37°C and 5% CO2. 
Calcium deposition was shown by Alizarin Red 
staining (Sigma-Aldrich, Louis St, MO) after 21 days 
incubation.  
MSCs (5 x 10
4
 cells/well) was supplemented 
by TNFα recombinant (5 and 10 ng/mL (BioLegend, 
San Diego, CA)) in 24-well plate using DMEM (Sigma-
Aldrich, Louis St, MO) then incubated for 24 hours at 
37°C with 5% CO2. Each experiment was performed 
in triplicate. The TNF-α recombinant medium was 
collected and analysed for TGFβ and IL-10 levels 
using ELISA assay.  
The levels of both TGF-β and IL-10 released 
in the culture supernatants from the various treatment 
groups were measured by specific ELISA. Briefly, 
according to the manufacturer’s instructions (Fine 
Test, Wuhan, China), TGF-β and IL-10 were 
calculated according to a standard curve constructed 
for each assay, and each assay was performed in 
triplicate. The colourimetric absorbance was recorded 
at a wavelength of 450 nm. 
Data are presented as the means ± standard 
deviation. All calculations were carried out using IBM 
SPSS 22.0 (IBM Corp., Armonk, NY, USA) was used 
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for statistical analysis. The statistical significance of 
the differences between the groups was assessed 
using one way-ANOVA and continued with Duncan 
post-hoc analysis. Correlation between IL-10 and the 
TGF-β level was done using one-tailed Pearson's test. 
P values: **, P < 0.001. 
 
 
Results 
 
Isolation of UC-MSCs was performed based 
on the capacity to plastic attachment under standard 
culture condition. Isolated cells were cultured for 2-3 
weeks in monolayer and used for differentiation 
analysis after 4 to 5 passages. The UC-MSCs were 
initially characterized by their elongated fibroblastic 
cellular phenotype (Figure 1a). Moreover, 
Osteogenesis was confirmed at day 21 of culture by 
immunodetection with Alizarin Red staining (Figure 
1b). 
 
Figure 1: a) UC-MSCs characterisation was based on their peculiar 
fibroblast-like (spindle shape) morphology; b) and osteogenic 
differentiation with Alizarin Red staining appears red colour  
 
The specific marker of UC-MSCs expression 
cultured in the media was evaluated as presented in 
Figure 2. We have characterised the expression 
pattern of UC-MSCs by flow cytometric analysis with 
the positive MSCs markers CD73, CD90 and CD105. 
 
Figure 2: Detection by flow cytometric demonstrates positive 
expression of three UC-MSCs markers. Populations are 99.2% 
positive for CD73, 96.7% positive for CD90 and 67.1% positive for 
CD105  
 
We subsequently quantify levels of IL-10 and 
TGF- β (Figure 3) by ELISA in triplicate. The analysis 
of TGF-β concentration showed that there was 
significantly increase in all treatments (p < 0.001) at 5 
ng/mL (64.09 ± 2.25 ng/mL) and 10 ng/mL (92.78 ± 
1.28 ng/mL) TNF-α dose. Furthermore, the IL-10 
concentration on all treatments showed the 
significantly increased (p < 0.001) at 5 ng/mL (533.12 
± 3.92 ng/mL) and 10 ng/mL (513.42 ± 4.31 ng/mL) 
TNF-α dose. In other side, we found the negative 
correlation between TGF-β and IL-10 level on 5 and 
10 ng/mL dose TNF-α treatment (p = 0.007, r =            
-0.933).  
   
Figure 3: a) ELISA assays for two treatment groups with doses 5 
and 10 ng/mL showed the highest concentration of TGF-β level at 
10 ng/mL TNF-α dose (92.78 ± 1.28 ng/mL), **, P < 0.001; b) 
Furthermore, the optimum concentration of IL-10 level in MSCs 
medium was 5 ng/mL TNF-α dose (533.12 ± 3.92 ng/mL). **, P < 
0.001 vs vehicle control; c) Moreover, the data demonstrated that 
there was signiﬁcant negative correlation between TGF-β and IL-10 
level on 5 and 10 ng/mL dose TNF-α treatment 
 
 
Discussion 
 
Inflammation is a cell protective response to 
eliminate various pathogens and preserve host 
integrity. MSCs as sensors of inflammatory may 
create both anti-inflammatory and proinflammatory 
effects when interacting to cell innate of the immune 
system or exposed by the various cytokine. Previous 
studies have shown that MCSs respond to 
inflammatory milieu by polarising either into MSCs 
type-2 with an immune-suppressive phenotype or 
MSCs type-1 with proinflammatory profile depend on 
Toll-Like Receptors (TLRs) type activation [7] [9] [21] 
[22]. Several studies have reported that 
immunosuppressive of MSCs occur through releasing 
various anti-inflammatory molecule including IL-10, 
ILra-1, PGE2, IDO, NO, TGF-β and TSG-6. The 
release of its anti-inflammatory molecules may occur 
through co-cultures of MSCs along with immune cells 
or under TNF-α, IL-1 and IFN-γ stimulation [15] [20]. 
The capacity of MSCs type-2 in suppressing the 
excessive inflammation and ameliorating immune 
disorders has opened new perspectives in clinical 
research, particularly in autoimmune disease.  
Our studies demonstrated that MSCs 
released IL-10 level was significantly increase at 5 
ng/mL and 10 ng/mL TNF-α (Figure 3a, P < 0.001). 
These data suggest that stimulation of low-dose TNF-
α (5 ng/mL) can promote the polarisation of MSCs into 
MSCs type-2. Under sufficient dose of TNF-α, MSCs 
upregulate the expression of TLR-3 leading to release 
of the various anti-inflammatory molecule including IL-
10 [8] [9]. The binding of TNF-α to TNFR-1 of MSCs 
resulted in the activation of NF-κβ and ERK signalling 
which produces cyclooxygenase-2 (COX2) and 
upregulates TLR-4 expression. TLR4-primed MSCs 
population which are known as MSCs type-1 exhibit a 
proinflammatory profile, including upregulation of 
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COX2 which increase PGE2 secretion. Specifically, 
PGE2 bound to EP2 and EP4 receptors of MSCs 
leading to the shift from MyD88-dependent 
proinflammatory (MyD88-independent pathway) to 
TRIF-TRAM mediated anti-inflammatory signal by a 
P110δ isoform of PI3k kinase resulting in IL-10 
secretion [23]. These facts suggest that MSCs are 
polarised into MSCs type-1 at initial stimulation of 
TNF-α characterised by COX2 secretion and then 
repolarise into MSCs type-2 along with the 
accumulation of inflammatory signal inside MSCs 
(Figure 4). 
In this study, the IL-10 level tends to decrease 
at 10 ng/mL than 5 ng/mL dose of TNF-α. A higher 
dose of TNF-α cause downregulation of MSCs type-2 
signalling and induce apoptotic program through TNF-
related apoptosis-inducing ligand-receptor 2 (TRAIL-
R2) pathway. The similar study has reported that 
TNF-α may induce apoptotic through TRAIL-R2 
pathway [24]. TRAIL-R2 is a specific cell surface 
receptor belongs to the TNF receptor superfamily [25] 
that also expressed in MSCs [26] [27]. Upon binding 
TNF-α, TRAIL-R2 initiates the recruitment of Fas-
associated protein with death domain (FADD) and 
procaspase-8 to form the death-inducing signalling 
complex (DISC) then activates downstream caspase-
3 and leads to apoptosis [28]. These suggest that the 
apoptosis pathway may be activated by higher doses 
of TNF-α. 
 
Figure 4: Schematic for MSCs polarisation under TNF-α stimulation; 
a) TNF-α binding to TNFR-1, then activating NF-κβ and ERK 
signalling which produces COX2 and (b) upregulate TLR-4 
expression leading to polarise MSCs into MSCs type-1 that exhibit 
proinflammatory profile; c) COX-2 upregulation resulting in the 
increase of PGE2 secretion. The binding accumulation of PGE2 to 
EP2 and EP4 receptors of MSCs triggering the shift of MyD88-
dependent proinflammatory (MyD88-independent pathway) to TRIF-
TRAM mediated anti-inflammatory signal by a P110δ isoform of the 
PI3k kinase, then repolarise to MSCs type 2 (anti-inflammatory 
phenotype) and inducing TRAF3-IRF3 resulting in IL-10 secretion. 
IL-10 inhibit NF-κβ/IKκβ cytoplasmic and NF-κβ nucleic then control 
the inflammatory milieu leading to the strong TGF-β secretion 
 
We also found that the significant increase of 
TGF-β level was about 4-fold than IL-10 level (Figure 
3b, P < 0.001) and shown a negative correlation 
between IL-10 and TGF-β production (Figure 3c). 
These finding suggest that MSC rapidly respond to 
inflammatory milieu by polarising into immune-
suppressive phenotype (MSCs type-2). The release of 
IL-10 has shown that the inflammation milieu is under 
control by MSCs, thus MSCs strongly produce other 
cytokine or growth factor including TGF-β production. 
This observation supports other studies revealing that 
IL-10 was elevated at 6 and 12 hour and then it 
decreased at 24 hour [15]. TGF-β is pleiotropic 
cytokines that is a well-known immunosuppressive 
molecule with important roles in immunoregulation 
[15] [19]. TGF-β inhibited inflammatory cytokine-
induced iNOS expression in a SMAD3-dependent 
manner. In this study, we explore MSCs without the 
co-culture with the immune cells, thus we don’t know 
exactly how the MSCs may interact and suppress the 
activated immune cells particularly in the case of an 
autoimmune disease. 
Based on our study, we conclude that the 5 
ng/mL dose of TNF-α is a sufficient dose for MSCs to 
suppress the inflammatory milieu. The higher increase 
of TGF-β is due to the controlled inflammation by IL-
10. 
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